SPEED study (N=87) | Pivotal trial (N=125) | |
---|---|---|
Revascularization (TIMI 2–3) (%) | 90.8 | 81.6 |
TIMI 2 (%) | 60.9 | 54.4 |
TIMI 3 (%) | 29.9 (N=86) | 27.2 |
Procedural SAEs (%) | 3.5 | 2.4 |
Symptomatic ICH (%) | 14 | 11 |
All-cause deaths (%) | 25.6 | 32.8 |
90-day mRS ≤ 2 (%) | 34.9 (N=63) | 25.0 |
ICH, intracranial hemorrhage; mRS, modified Rankin scores; TIMI, Thrombolysis In Myocardial Infarction; SAE, serious adverse event.